Showing 1351-1360 of 5757 results for "".
Dupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sLaser Innovations on the Horizon
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-innovations-on-the-horizon/18534/Jill Waibel, MD discusses advances in lasers and what's on the horizon. She shares insights on a new and improved pulsed dye laser plus RF; fractional applications being investigated for scars, vitiligo, wrinkles, and more; plus devices for vaginal rejuvenation.Eyes Have It: Bloodless Blephs and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/eyes-have-it-bloodless-blephs-and-more/18728/Demand for treatments around the eye continue to grow; patients want big results but little downtime. Dr. Niamtu discusses his "bloodless bleph" and other uses for fillers and toxins.PsO Many Options: The Expanded Psoriasis Landscape
https://practicaldermatology.com/topics/psoriasis/pso-many-options-the-expanded-psoriasis-landscape/18749/By Jeffrey Weinberg, MD and Seemal R. Desai, MDWith many new therapies coming out in oral, topical, and biologic forms, there are fewer unmet needs in psoriasis management now than ever before. Dr. Weinberg navigates the therapeutic landscape.Telemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse andOnline Reputation Management Update
https://practicaldermatology.com/topics/practice-management/online-reputation-management-update/18658/Protecting your online reputation is crucial to your digital marketing success. If you think it's all about spotting and hiding bad reviews, you're wrong. Learn how to build and protect a stellar online reputation for your dermatology practice and how it will actually boost SEO. The Ekwa Marketing t10 Tips for Managing Hidradenitis Suppurativa
https://practicaldermatology.com/issues/april-2025/10-tips-for-managing-hidradenitis-suppurativa/35602/In an effort to assist the working dermatologist, we have provided the following HS management guide, which supplies actionable insights into optimizing HS management, emphasizing the importance of individualized care, timely interventions, and collaboration with multidisciplinary teams.Analyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuJames Del Rosso, DO: Thoughts on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/james-del-rosso-do-thoughts-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24173/James Q. Del Rosso, DO, a dermatologist and president of The American Acne and Rosacea Society (AARS), weighs in on a recent report from Valisure which finds that benzene can form at elevated levels in products for acne that contain benzoyl peroxide (BPO). The interview was conducted by Neal Bhatia,DermWireTV: Dermatologists React to the Valisure Report; FDA Approves New Treatment for Frown Lines
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-dermatologists-react-valisure-report-fda-approves-new-treatment-frown-lines/24157/In this episode of DermWireTV, dermatologists react to the recent Valisure report that found elevated levels of benzene when studied under laboratory conditions in certain acne products containing BPO; the FDA approves a new treatment option for glabellar lines; and the PA Perspectives series addres